Downloads: 99

Files in This Item:
File Description SizeFormat 
20406207221142487.pdf1.31 MBAdobe PDFView/Open
Full metadata record
DC FieldValueLanguage
dc.contributor.authorShimazu, Yutakaen
dc.contributor.authorKanda, Junyaen
dc.contributor.authorKaneko, Hitomien
dc.contributor.authorImada, Kazunorien
dc.contributor.authorYamamura, Ryosukeen
dc.contributor.authorKosugi, Satoruen
dc.contributor.authorShimura, Yujien
dc.contributor.authorIto, Tomokien
dc.contributor.authorFuchida, Shin-ichien
dc.contributor.authorUchiyama, Hitojien
dc.contributor.authorFukushima, Kentaroen
dc.contributor.authorYoshihara, Satoshien
dc.contributor.authorHanamoto, Hitoshien
dc.contributor.authorTanaka, Hirokazuen
dc.contributor.authorUoshima, Nobuhikoen
dc.contributor.authorOhta, Kensukeen
dc.contributor.authorYagi, Hideoen
dc.contributor.authorShibayama, Hirohikoen
dc.contributor.authorOnda, Yoshiyukien
dc.contributor.authorTanaka, Yasuhiroen
dc.contributor.authorAdachi, Yokoen
dc.contributor.authorMatsuda, Mitsuhiroen
dc.contributor.authorIida, Masatoen
dc.contributor.authorMiyoshi, Takashien
dc.contributor.authorMatsui, Toshimitsuen
dc.contributor.authorTakahashi, Ryoichien
dc.contributor.authorTakakuwa, Teruhitoen
dc.contributor.authorHino, Masayukien
dc.contributor.authorHosen, Naokien
dc.contributor.authorNomura, Shosakuen
dc.contributor.authorShimazaki, Chihiroen
dc.contributor.authorMatsumura, Itaruen
dc.contributor.authorTakaori-Kondo, Akifumien
dc.contributor.authorKuroda, Junyaen
dc.contributor.alternative島津, 裕ja
dc.contributor.alternative諫田, 淳也ja
dc.contributor.alternative髙折, 晃史ja
dc.date.accessioned2023-02-20T10:20:36Z-
dc.date.available2023-02-20T10:20:36Z-
dc.date.issued2022-
dc.identifier.urihttp://hdl.handle.net/2433/279367-
dc.description.abstractBACKGROUND: Daratumumab is one of the most widely used treatments for relapsed/refractory multiple myeloma (MM) patients. However, not all patients achieve a lasting therapeutic response with daratumumab. OBJECTIVES: We hypothesized that a durable response to daratumumab could be predicted by the balance between the MM tumor burden and host immune status. DESIGN: We conducted a retrospective study using the real-world data in the Kansai Myeloma Forum (KMF) database. METHODS: We retrospectively analyzed 324 relapsed/refractory MM patients who were treated with daratumumab in the KMF database. RESULTS: In this study, 196 patients were treated with daratumumab, lenalidomide, and dexamethasone (DLd) regimen and 128 patients were treated with daratumumab, bortezomib, and dexamethasone (DBd) regimen. The median age at treatment, number of prior treatment regimens and time-to-next-treatment (TTNT) were 68, 4 and 8.02 months, respectively. A multivariate analysis showed that the TTNT under the DLd regimen was longer with either higher monocyte counts (analysis 1), higher white blood cell (WBC) counts (analysis 2), lower β2 microglobulin (B2MG < 5.5 mg/L) or fewer prior regimens (<4). No parameters were correlated with TTNT under the DBd regimen. CONCLUSION: We propose a simple scoring model to predict a durable effect of the DLd regimen by classifying patients into three categories based on either monocyte counts (0 points for ⩾200/μl; 1 point for <200/μl) or WBC counts (0 points for ⩾3500/μl; 1 point for <3500/μl) plus B2MG (0 points for <5.5 mg/L; 1 point for ⩾5.5 mg/L). Patients with a score of 0 showed significantly longer TTNT and significantly better survival compared to those with a score of 1 or 2 (both p < 0.001). To confirm this concept, our results will need to be validated in other cohorts.en
dc.language.isoeng-
dc.publisherSAGE Publicationsen
dc.rights© The Author(s), 2022.en
dc.rightsThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).en
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/-
dc.subjectβ2 microglobulinen
dc.subjectdaratumumaben
dc.subjectmonocyteen
dc.subjectmultiple myelomaen
dc.subjectpredictive markersen
dc.titleMonocyte or white blood cell counts and β<sub>2</sub> microglobulin predict the durable efficacy of daratumumab with lenalidomideen
dc.typejournal article-
dc.type.niitypeJournal Article-
dc.identifier.jtitleTherapeutic Advances in Hematologyen
dc.identifier.volume13-
dc.relation.doi10.1177/20406207221142487-
dc.textversionpublisher-
dc.identifier.artnum20406207221142487-
dc.identifier.pmid36530751-
dcterms.accessRightsopen access-
dc.identifier.pissn2040-6207-
dc.identifier.eissn2040-6215-
Appears in Collections:Journal Articles

Show simple item record

Export to RefWorks


Export Format: 


This item is licensed under a Creative Commons License Creative Commons